Congress Materials

Medical Information
Ireland
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a healthcare professionalYes, I am a healthcare professional
SelectI am a healthcare professionalYes, I am a healthcare professional
I am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal
SelectI am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal

If you don't reside in Ireland, please click here

The medical information on this site is intended only for healthcare professionals in the Republic of Ireland. The products discussed herein may have different product labeling in other countries.

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Sherlock SP, Hwang S, Aghamolaey H, Ahlgren A, Widholm P, Dahlqvist Leinhard O, Karlsson M March 22, 2023 MDA 2023 Duchenne Muscular Dystrophy

Relationship between quantitative MRI measures and future functional changes in boys with Duchenne muscular dystrophy (DMD)

View Presentation
Poster
Posner N, Manjelievskaia J, Talaga AK, Richards M, Lew CR, Merla V, Alvir JMJ, Nelson SF March 22, 2023 MDA 2023 Duchenne Muscular Dystrophy

Treatment utilization by race among medicaid-insured males with Duchenne muscular dystrophy (DMD) using U.S. real-world data

View Presentation
Oral Presentation
Sherlock SP, Schwartz PF, Yong FH, Butterfield RJ, Shieh PB, Smith EC, McDonnell TG, Ryan KA, Binks M March 22, 2023 MDA 2023 Duchenne Muscular Dystrophy

Two-year muscle MRI observations from a Phase 1b trial of fordadistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy

View Presentation